Hospital Universitari Parc Taulí

Sabadell, Barcelona 08208

1 studies enrolling now · 3 studies all time

What they study most

Advanced Solid Tumor, Anal Cancer, Anal Neoplasm, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Carcinoma, Squamous Cell of Head and Neck, Castration-Resistant Prostatic Cancer, HER-2 Positive Breast Cancer, Head and Neck Squamous Cell Carcinoma, Hormone Refractory Prostatic Cancer, Laryngeal Squamous Cell Carcinoma

Studies at this site

• A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors — Recruiting now
• A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors — Stopped early
• Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer — Completed